The Development of STING Agonists and Emerging Results as a Cancer Immunotherapy.
Jacobi B HinesAlec J KacewRandy F SweisPublished in: Current oncology reports (2023)
Preclinical data has shown that the addition of a STING agonist enhances the effect of current treatments such as immune checkpoint inhibitor antibodies and radiation therapy. Early phase trials have demonstrated modest efficacy of STING agonists and revealed new mechanistic and technical challenges. STING agonists are a new class of agents that activate the immune response to improve tumor control. A wide range of preclinical experiments, translational data, and ongoing clinical trials support the therapeutic use of STING agonists in patients. Trials to determine optimal drug combinations and novel delivery mechanisms are continuing in development.
Keyphrases
- radiation therapy
- immune response
- clinical trial
- end stage renal disease
- electronic health record
- ejection fraction
- newly diagnosed
- chronic kidney disease
- big data
- cell therapy
- peritoneal dialysis
- randomized controlled trial
- squamous cell carcinoma
- emergency department
- dendritic cells
- single cell
- stem cells
- inflammatory response
- toll like receptor
- artificial intelligence
- radiation induced
- medical education